Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Chief Financial Officer | October 05, 2026 | October 07, 2026 |
| REVVITY, INC.PKI · Entity 3382 | Please See Remarks | June 24, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,125 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 1,454 · Balance 60,829 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-10-05 · Tax withholding · Disposed 704 · Balance 60,125 F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 1,454 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
REVVITY, INC.
Report date June 24, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,577 |
Ending reported balance
After 2022-06-24 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-06-24 · Sale · Disposed 2,072 · Balance 30,530 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022. F2: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $144.27 to $145.11. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Row 2 · 2022-06-24 · Sale · Disposed 2,290 · Balance 28,240 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022. F3: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $145.27 to $146.26. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Row 3 · 2022-06-24 · Sale · Disposed 663 · Balance 27,577 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022. F4: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $146.28 to $146.40. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Mock on May 23, 2022.
F2: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $144.27 to $145.11. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $145.27 to $146.26. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F4: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $146.28 to $146.40. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2025 Filed Jan 6, 2025 21:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000785 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,169 Underlying: Common Stock · 1,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 780 | $42.00 | $32,760.00 |
DisclosureSEC source: 0001127602-25-000785 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,739 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-000785 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:55 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 188,761 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028780 · form4.xml · derivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,761 Underlying: Common Stock · 188,761 shares Expires not disclosed F1 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F1 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,420 | $42.79 | $60,760.52 |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · nonDerivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,066 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs and PSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · derivative · entry 7 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,326 Underlying: Common Stock · 1,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F6 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · derivative · entry 6 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,959 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionPerformance Stock Units · Derivative | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · derivative · entry 5 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,326 Underlying: Common Stock · 1,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units convert into common stock on a one-for-one basis. F1 · kind: Performance stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. F4 · derivative.expiration_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · nonDerivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028301 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Performance stock units convert into common stock on a one-for-one basis. F1 · price: Performance stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 20:19 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 715 | $60.12 | $42,985.80 |
DisclosureSEC source: 0001127602-24-025328 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,505 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025328 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,622 Underlying: Common Stock · 1,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-025328 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 162 | $78.03 | $12,640.21 |
DisclosureSEC source: 0001127602-24-023239 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,767 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,321 | $79.39 | $104,880.66 |
DisclosureSEC source: 0001127602-24-023162 · form4.xml · nonDerivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,600 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of performance stock units and restricted stock units. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023239 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,288 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023239 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023162 · form4.xml · derivative · entry 5 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,652 Underlying: Common Stock · 1,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionPerformance Stock Units · Derivative | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023162 · form4.xml · derivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,652 Underlying: Common Stock · 1,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units convert into common stock on a one-for-one basis. F1 · kind: Performance stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. F4 · derivative.expiration_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023162 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023162 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Performance stock units convert into common stock on a one-for-one basis. F1 · price: Performance stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 689 | $118.24 | $81,465.36 |
DisclosureSEC source: 0001127602-24-020247 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,269 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020247 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,075 Underlying: Common Stock · 1,452 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-020247 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 691 | $140.72 | $97,237.38 |
DisclosureSEC source: 0001127602-24-017764 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,506 F2 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionPerformance Stock Units · Derivative | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017764 · form4.xml · derivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,978 Underlying: Common Stock · 1,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units convert into common stock on a one-for-one basis. F1 · kind: Performance stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. F3 · derivative.expiration_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantPerformance Stock Units · Derivative | 5,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017764 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,304 Underlying: Common Stock · 5,304 shares Expires not disclosed F1 · derivative.exercise_price: Performance stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. F3 · derivative.expiration_date: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017764 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Performance stock units convert into common stock on a one-for-one basis. F1 · price: Performance stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:36 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 183 | $144.50 | $26,444.36 |
DisclosureSEC source: 0001127602-24-016987 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,871 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 648 | $162.47 | $105,282.89 |
DisclosureSEC source: 0001127602-24-016777 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,726 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016987 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,617 Underlying: Common Stock · 328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016987 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016777 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,978 Underlying: Common Stock · 1,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016777 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 705 | $101.93 | $71,859.31 |
DisclosureSEC source: 0001127602-24-012708 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,048 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012708 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,527 Underlying: Common Stock · 1,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-012708 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:33 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 647 | $94.57 | $61,188.08 |
DisclosureSEC source: 0001127602-24-007949 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,300 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007949 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,945 Underlying: Common Stock · 1,315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-007949 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 5,304 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007637 · form4.xml · derivative · entry 5 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,304 Underlying: Common Stock · 5,304 shares Expires not disclosed F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 60,216 | $0.00 Strike: $96.20 | $0.00 |
DisclosureSEC source: 0001127602-24-007637 · form4.xml · derivative · entry 4 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,216 Underlying: Common Stock · 60,216 shares Expires 2034-02-27 F3 · derivative.exercise_date: 50% of this option will vest and become exercisable on February 27, 2026 and the remaining 50% will vest and become exercisable on February 27, 2027, subject to the recipient's continued service. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 12,377 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007637 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,377 Underlying: Common Stock · 12,377 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 23,635 | $0.00 Strike: $96.20 | $0.00 |
DisclosureSEC source: 0001127602-24-007637 · form4.xml · derivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,635 Underlying: Common Stock · 23,635 shares Expires 2034-02-27 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 772 | $109.75 | $84,730.55 |
DisclosureSEC source: 0001127602-24-001125 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,632 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-001125 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,980 Underlying: Common Stock · 1,452 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-001125 · form4.xml · nonDerivative · entry 1 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,858 | $102.50 | $292,952.72 |
DisclosureSEC source: 0001127602-23-025714 · form4.xml · nonDerivative · entry 2 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,952 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 5,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-025714 · form4.xml · derivative · entry 3 Mock James M · CIK 0001736359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,432 Underlying: Common Stock · 5,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.